GlassScriptPhysician profile
Scott C Morgan
NPI 1679547947
$3,110.05
in general payments reported to CMS, 2019-2025
29 companies · $795 in 2025
The $795 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.06 · 2021: $658 · 2022: $404 · 2023: $586 · 2024: $646 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $612.59 | 2022-2025 | |
| Olympus America INC. | $452.25 | 2021-2025 | Itind System, Soltive |
| Axonics, INC. | $251.53 | 2021-2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $243.94 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $204.32 | 2021-2022 | |
| Allergan, INC. | $178.48 | 2021 | |
| Urogen Pharma, INC. | $156.42 | 2021-2025 | |
| Coloplast Corp | $125.51 | 2021-2024 | Saffron |
| Boston Scientific Corporation | $111.42 | 2020-2025 | Axonics |
| Ferring Pharmaceuticals INC. | $88.19 | 2025 | Adstiladrin |
| Pfizer INC. | $76.76 | 2021-2023 | |
| Procept Biorobotics Corporation | $69.85 | 2024 | Aquabeam System |
| Laborie Medical Technologies Corp. | $66.96 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Calyxo, INC. | $59.98 | 2024 | Cvac Aspiration System |
| Bayer Healthcare Pharmaceuticals INC. | $52.05 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $49.41 | 2025 | Xiaflex |
| Novo Nordisk INC | $48.45 | 2023 | Rybelsus, Ozempic |
| Myriad Genetic Laboratories, INC. | $29.91 | 2021 | |
| Corcept Therapeutics | $29.27 | 2023 | Korlym |
| Urovant Sciences INC | $28.12 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $22.56 | 2024 | Signifor Lar, Isturisa |
| Medtronic, INC. | $22.37 | 2025 | Interstim |
| Immunitybio, INC. | $21.15 | 2025 | |
| Janssen Biotech, INC. | $20.95 | 2025 | Erleada |
| Endo Pharmaceuticals INC. | $20.50 | 2023 | Xiaflex, Aveed, Edex |
| Tolmar, INC. | $18.75 | 2025 | Eligard |
| Tandem Diabetes Care, INC. | $17.97 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $15.36 | 2023 | Keytruda, Lynparza |
| Dentsply Ih INC. | $15.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.